Antidepressant eases radiation-related mouth pain in head, neck cancer

October 29, 2012

An oral rinse of the antidepressant doxepin significantly eased pain associated with oral mucositis in patients receiving radiation therapy for cancers of the head and neck, a study led by Mayo Clinic found. The findings were presented at the American Society for Radiation Oncology annual meeting in Boston.

"Oral mucositis or mouth sores is a painful and debilitating side effect of ," says principal investigator Robert Miller, M.D., a at Mayo Clinic. "Our findings represent a new standard of care for treating this condition."

Doxepin rinse does not cause the side effects associated with narcotic pain medicines, Dr. Miller says.

The Phase III study assessed the effectiveness of doxepin oral rinse versus placebo in 155 patients receiving radiation therapy for . Patients received a single blinded dose of doxepin on day one and crossed over to the opposite study arm on a subsequent day. Patients reported pain associated with oral mucositis on a pain questionnaire with a scale of 0 to 10 administered at baseline and then at five, 15, 30, 60, 120 and 240 minutes after rinsing with doxepin. Patients could continue doxepin after the study, and 64 percent did so. Doxepin was well tolerated, though stinging, burning, unpleasant taste and drowsiness were reported as side effects.

Explore further: Oral temperature changes in head and neck cancer patients predicts side effect severity

Related Stories

Recommended for you

Scientists block breast cancer cells from hiding in bones

May 25, 2016

Scientists at the Duke Cancer Institute have identified a molecular key that breast cancer cells use to invade bone marrow in mice, where they may be protected from chemotherapy or hormonal therapies that could otherwise ...

Genetic sequencing reveals drug resistance growth

May 25, 2016

The rate at which genetically mutated cancer cells grow may help explain why patients with a common form of leukemia develop treatment resistance, according to new research led by a Weill Cornell Medicine investigator. The ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.